GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » Operating Income

Vaxcyte (Vaxcyte) Operating Income : $-432.09 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Operating Income?

Vaxcyte's Operating Income for the three months ended in Mar. 2024 was $-114.35 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-432.09 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Vaxcyte's Operating Income for the three months ended in Mar. 2024 was $-114.35 Mil. Vaxcyte's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Vaxcyte's Operating Margin % for the quarter that ended in Mar. 2024 was %.

Vaxcyte's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vaxcyte's annualized ROC % for the quarter that ended in Mar. 2024 was -100.01%. Vaxcyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -302.28%.


Vaxcyte Operating Income Historical Data

The historical data trend for Vaxcyte's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Operating Income Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial -53.92 -87.10 -102.09 -207.33 -388.28

Vaxcyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70.54 -84.68 -111.39 -121.67 -114.35

Vaxcyte Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-432.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxcyte  (NAS:PCVX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vaxcyte's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-457.384 * ( 1 - 0% )/( (330.132 + 584.523)/ 2 )
=-457.384/457.3275
=-100.01 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1407.917 - 127.169 - ( 1080.227 - max(0, 145.338 - 1095.954+1080.227))
=330.132

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2091.305 - 76.814 - ( 1486.518 - max(0, 87.104 - 1517.072+1486.518))
=584.523

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Vaxcyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-457.384/( ( (145.311 + max(-122.498, 0)) + (157.315 + max(-65.357, 0)) )/ 2 )
=-457.384/( ( 145.311 + 157.315 )/ 2 )
=-457.384/151.313
=-302.28 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 15.727) - (127.169 + 0 + 11.056)
=-122.498

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 14.545) - (76.814 + 0 + 3.088)
=-65.357

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Vaxcyte's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-114.346/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Vaxcyte Operating Income Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxcyte (Vaxcyte) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.
Executives
Andrew Guggenhime officer: CFO, CBO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Grant Pickering director, officer: President & CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman officer: SVP, Gen Counsel & Corp Sec C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jim Wassil officer: Chief Operating Officer C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Elvia Cowan officer: See Remarks Section C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jeff Fairman officer: VP, Research C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer officer: SVP Process Dev, Manufacturing C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck director C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal officer: SVP Cml Mfg & Supply Chain C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau director C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Teri Loxam director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Jane Wright Mitchell officer: General Counsel C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Robert Lorne Hopfner director C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111

Vaxcyte (Vaxcyte) Headlines

From GuruFocus